NCT01679080 is a Phase 2 clinical trial of Zoledronic acid in Osteogenesis Imperfecta, sponsored by University of Aarhus.

Who is sponsoring NCT01679080?

NCT01679080 is sponsored by University of Aarhus.

What drugs are being tested in NCT01679080?

Interventions in NCT01679080: Zoledronic acid, Teriparatide, No active treatment.

What condition does NCT01679080 study?

NCT01679080 studies Osteogenesis Imperfecta.

Is NCT01679080 still recruiting?

NCT01679080 is currently terminated. Last updated 22 June 2021.

Last reviewed 2021-06-22 · How we verify

NCT01679080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

Terminated Phase 2 Last updated 22 June 2021

What this trial tests

Phase 2 trial testing Zoledronic acid in Osteogenesis Imperfecta in 9 participants. Terminated before completion.

Timeline

1 November 2012

Primary endpoint
1 July 2020

1 June 2021

Quick facts

Lead sponsor	University of Aarhus
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 November 2012
Primary completion	1 July 2020
Estimated completion	1 June 2021
Sites	3 locations across Denmark

Drugs / interventions tested

Zoledronic acid (ZOLEDRONIC ACID) — full drug profile →
Teriparatide — full drug profile →
No active treatment

Conditions studied

Osteogenesis Imperfecta — all drugs for Osteogenesis Imperfecta →

Sponsor

University of Aarhus

Who can join

Adults 22 to 70, any sex, with Osteogenesis Imperfecta. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Bone Mineral Density (BMD)
Time frame: Three years
Dual-energy X-ray absorptiometry scans are performed at the lumbar spine, hip and whole body twice yearly. The value of the lumbar BMD is the primary outcome.

Sponsor's own description

Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o. The aim of the present study is to investigate the effect of treatment of adult OI patients with bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass, fracture risk and quality of life. The investigators will therefore conduct a double blind, placebo controlled trial, taking genotype and previous antiresorptive therapy into account.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Collagen transport and related pathways in Osteogenesis Imperfecta.
Claeys L, Storoni S, Eekhoff M, Elting M, et al · · 2021 · cited 67× · PMID 34169326 · DOI 10.1007/s00439-021-02302-2

Verify or expand the search:

Other trials of Zoledronic acid

Trials testing the same drug.

NCT06374459 — Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br · Phase 1, PHASE2 · recruiting
NCT06135298 — FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA · Phase 4 · completed
NCT05866172 — HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC · Phase 3 · unknown
NCT06051344 — Effect of Zoledronic Acid in Primary Knee Osteoarthritis · Phase 4 · unknown
NCT05405894 — Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation · unknown

Other recruiting trials for Osteogenesis Imperfecta

Currently open trials in the same condition.

NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
NCT05972551 — Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Oste · Phase 3 · recruiting
NCT05927389 — Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta · NA · recruiting
NCT06193642 — Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data · NA · active not recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01679080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 22 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01679080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing